Beam Therapeutics annual shareholders’ equity
2019
2020
2021
2022
2023
2024
2025
Beam Therapeutics Shareholders’ Equity Growth & History (BEAM)
Beam Therapeutics's shareholders’ equity was $1.24B for fiscal 2025.
View full Beam Therapeutics company overviewBeam Therapeutics annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.24B | $504.8M | +68.82% |
| 2024 | 2024-12-31 | $733.5M | −$247.8M | −25.25% |
| 2023 | 2023-12-31 | $981.3M | $247.9M | +33.79% |
| 2022 | 2022-12-31 | $733.5M | −$93.3M | −11.28% |
| 2021 | 2021-12-31 | $826.7M | $581.2M | +236.67% |
| 2020 | 2020-12-31 | $245.6M | $446.7M | — |
| 2019 | 2019-12-31 | −$201.1M | — | — |
Beam Therapeutics quarterly shareholders’ equity
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.07B | $14.1M | +1.34% |
| Q1 2026 | 2026-03-31 | $1.16B | $35.0M | +3.10% |
| Q4 2025 | 2025-12-31 | $1.24B | $504.8M | +68.82% |
| Q3 2025 | 2025-09-30 | $966.0M | $174.7M | +22.08% |
| Q2 2025 | 2025-06-30 | $1.05B | $199.2M | +23.32% |
| Q1 2025 | 2025-03-31 | $1.13B | $216.0M | +23.64% |
| Q4 2024 | 2024-12-31 | $733.5M | −$247.8M | −25.25% |
| Q3 2024 | 2024-09-30 | $791.3M | $12.4M | +1.59% |
| Q2 2024 | 2024-06-30 | $854.1M | $42.5M | +5.23% |
| Q1 2024 | 2024-03-31 | $913.5M | $152.0M | +19.96% |
| Q4 2023 | 2023-12-31 | $981.3M | $247.9M | +33.79% |
| Q3 2023 | 2023-09-30 | $778.9M | $64.5M | +9.02% |
| Q2 2023 | 2023-06-30 | $811.6M | $11.5M | +1.43% |
| Q1 2023 | 2023-03-31 | $761.5M | −$67.6M | −8.15% |
| Q4 2022 | 2022-12-31 | $733.5M | −$93.3M | −11.28% |
| Q3 2022 | 2022-09-30 | $714.5M | −$139.3M | −16.32% |
| Q2 2022 | 2022-06-30 | $800.2M | $251.6M | +45.87% |
| Q1 2022 | 2022-03-31 | $829.1M | $406.6M | +96.26% |
| Q4 2021 | 2021-12-31 | $826.7M | $581.2M | +236.67% |
| Q3 2021 | 2021-09-30 | $853.8M | $653.7M | +326.76% |
| Q2 2021 | 2021-06-30 | $548.6M | $317.7M | +137.65% |
| Q1 2021 | 2021-03-31 | $422.4M | $161.0M | +61.61% |
| Q4 2020 | 2020-12-31 | $245.6M | $446.7M | — |
| Q3 2020 | 2020-09-30 | $200.1M | — | — |
| Q2 2020 | 2020-06-30 | $230.8M | — | — |
| Q1 2020 | 2020-03-31 | $261.4M | — | — |
| Q4 2019 | 2019-12-31 | −$201.1M | — | — |
Beam Therapeutics shareholders’ equity trends
Over the last five fiscal years, Beam Therapeutics's shareholders’ equity increased from $245.6M to $1.24B, a change of $992.8M. The latest reported quarter, Q2 2026, shows $1.07B.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Beam Therapeutics source filings ↗Community posts
Beam reports durable protein correction with experimental AATD therapy
Beam Therapeutics ($BEAM) presented updated Phase 1/2 results for BEAM-302, its experimental gene-editing treatment for alpha-1 antitrypsin deficiency. The presentation covered 29 patients given a single dose, with follow-up extending to 18 ...